Allt inom mfn-ext-nq
Nanexa receives Japanese patent approval for specific PharmaShell structure
The approval strengthens Nanexa’s patent portfolio, with additional patent applications filed in other strategically important countries
Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market
The collaboration provides further proof that PharmaShell atomic layer deposition technology is of interest to major pharma companies. Nanexa is poised for further partnerships in the treatment of other chronic conditions.